Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 5th edition, 486 pages

Free download

  Malignant Melanoma

  Free Subscription


2 Ann Surg Oncol
1 Arch Pathol Lab Med
1 BMC Cancer
1 Br J Cancer
1 Br J Dermatol
1 Cancer Res
2 Clin Cancer Res
1 J Am Acad Dermatol
1 Nat Med
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg Oncol

  1. LO M, Peach H, Moncrieff M
    ASO Author Reflections: Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management.
    Ann Surg Oncol. 2020 Oct 20. pii: 10.1245/s10434-020-09197.

  2. BOGACH J, Wright FC, Austin J, Cheng SY, et al
    Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study.
    Ann Surg Oncol. 2020 Oct 16. pii: 10.1245/s10434-020-09224.
    PubMed         Abstract available

    Arch Pathol Lab Med

  3. CHO WC, Wang WL, Milton DR, Ingram DR, et al
    Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma.
    Arch Pathol Lab Med. 2020 Oct 14. pii: 445970. doi: 10.5858/arpa.2020-0330.
    PubMed         Abstract available

    BMC Cancer

  4. WU CE, Yang CK, Peng MT, Huang PW, et al
    The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    BMC Cancer. 2020;20:1018.
    PubMed         Abstract available

    Br J Cancer

  5. BHAVE P, Pallan L, Long GV, Menzies AM, et al
    Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01121.
    PubMed         Abstract available

    Br J Dermatol

  6. GHIASVAND R, Khosrotehrani K, Hughes MCB, von Schuckmann LA, et al
    Patient age and risk of recurrence of primary melanoma at high risk of spread.
    Br J Dermatol. 2020 Oct 14. doi: 10.1111/bjd.19601.
    PubMed         Abstract available

    Cancer Res

  7. PAUDEL BB, Lewis JE, Hardeman KN, Hayford CE, et al
    An Integrative Gene Expression and Mathematical Flux Balance Analysis Identifies Targetable Redox Vulnerabilities in Melanoma Cells.
    Cancer Res. 2020;80:4565-4577.
    PubMed         Abstract available

    Clin Cancer Res

  8. CHUA V, Mattei J, Han A, Johnston L, et al
    The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).
    Clin Cancer Res. 2020 Oct 15. pii: 1078-0432.CCR-20-2536.
    PubMed         Abstract available

  9. MARSAVELA G, Lee J, Calapre L, Wong SQ, et al
    Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy.
    Clin Cancer Res. 2020 Oct 16. pii: 1078-0432.CCR-20-2251.
    PubMed         Abstract available

    J Am Acad Dermatol

  10. NAVARRETE-DECHENT C, Aleissa S, Connolly K, Hibler BP, et al
    Clinical size is a poor predictor of invasion in melanoma of the lentigo maligna type.
    J Am Acad Dermatol. 2020 Oct 20. pii: S0190-9622(20)32835.
    PubMed         Abstract available

    Nat Med

  11. CEREZO-WALLIS D, Contreras-Alcalde M, Troule K, Catena X, et al
    Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.
    Nat Med. 2020 Oct 19. pii: 10.1038/s41591-020-1073.
    PubMed         Abstract available

    PLoS One

  12. PORTO AC, Pinto Blumetti T, Oliveira Santos Filho IDA, Calsavara VF, et al
    Primary cutaneous melanoma of the scalp: Patterns of clinical, histological and epidemiological characteristics in Brazil.
    PLoS One. 2020;15:e0240864.
    PubMed         Abstract available

  13. HO JC, Lee CH, Hong CH
    Targeting steroid receptor RNA activator (SRA), a long non-coding RNA, enhances melanogenesis through activation of TRP1 and inhibition of p38 phosphorylation.
    PLoS One. 2020;15:e0237577.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.